12 Steps to Prevent Dementia: Plus the Biochemical Layer Most Guides Miss

Introduction: The 45% Opportunity

Roughly 57 million people worldwide currently live with dementia, a number projected to reach 153 million by 2050. A new case is diagnosed somewhere in the world every three seconds. For most people, those figures feel abstract until the disease touches someone they love.

Here is the hopeful counterpoint. The 2024 Lancet Commission now estimates that up to 45% of global dementia cases could be prevented or delayed by addressing 14 modifiable risk factors. Many readers recognize the familiar “12 steps” framing from the 2020 Lancet report. The 2024 update expanded that list to 14, adding untreated vision loss and high LDL cholesterol.

This article covers both. Part 1 walks through the 14 lifestyle risk factors, the essential foundation. Part 2 introduces a biochemical layer that mainstream guides systematically overlook: plasmalogen depletion. Lifestyle changes are necessary, but they may be insufficient without also protecting the brain’s biochemical foundation. With only 30% of people aware they can act on their risk at all, this guide matters.

Understanding the Lancet Commission Framework: From 12 to 14 Risk Factors

The Lancet Commission is a standing expert panel that synthesizes global epidemiological evidence to identify modifiable dementia risk factors across the life course. The original 2020 report named 12 factors. The 2024 update brought the total to 14.

The framework is organized by life stage: early life, midlife (ages 40 to 65), and later life. Midlife interventions are disproportionately more effective than late-life ones. From age 55 to 95, the lifetime risk of developing dementia in the United States is 42%, according to Nature Medicine research summarized by Johns Hopkins.

The framework is behavioral and clinical. It does not address the lipid-membrane dimension covered in Part 2.

Early Life Risk Factor: Build the Foundation Before Midlife

The single early-life factor is low education. The cognitive reserve hypothesis explains why: higher educational attainment builds neural connections that provide resilience against dementia-related brain changes. The practical takeaway is encouraging. Lifelong learning, whether formal or informal, continues building reserve at any age. This factor disproportionately affects lower-resourced populations, which is why the Commission emphasizes equity.

Midlife Risk Factors (Ages 40 to 65): The Highest-Leverage Window

Midlife is the highest-leverage prevention window. The Johns Hopkins/ARIC study found that managing diabetes and hypertension in middle age offers the greatest long-term brain protection. Dementia risk is lowest in people with healthy midlife behaviors, making this section the most actionable for the core audience.

Hearing Loss

Untreated hearing loss is one of the largest single modifiable risk factors. The mechanisms include social isolation, reduced cognitive stimulation, and the heavy cognitive load of effortful listening, all of which accelerate brain atrophy. Action step: Schedule regular hearing assessments and use hearing aids promptly when indicated.

Hypertension

Sustained high blood pressure damages small cerebral blood vessels, reducing oxygen and nutrient delivery to the brain. Midlife hypertension is especially damaging because it acts over decades before symptoms appear. Action steps: Monitor blood pressure, reduce dietary sodium, stay active, and adhere to prescribed medication.

Obesity

Obesity drives chronic systemic inflammation, insulin resistance, and vascular damage. It also fuels both diabetes and hypertension, compounding risk. Action steps: Maintain a healthy BMI through diet and activity. Mediterranean-style eating has the strongest evidence base.

Smoking

Smoking accelerates cerebrovascular disease and oxidative stress, both of which damage brain tissue. Cessation at any age reduces risk, though earlier quitting yields greater benefit. Action step: Use evidence-based cessation programs; nicotine replacement and behavioral support improve quit rates.

High LDL Cholesterol (New in 2024)

One of two new 2024 additions, elevated LDL contributes to atherosclerosis, reducing cerebral blood flow, and may directly influence amyloid-beta accumulation. Notably, cholesterol dysregulation is also linked to plasmalogen depletion and APOE ε4 pathways, a connection expanded in Part 2. Action steps: Reduce saturated and trans fats, stay active, and use lipid-lowering therapy when clinically indicated.

Depression

Depression is both a risk factor for and an early symptom of dementia, making treatment important regardless of causality. Mechanisms include neurotoxic cortisol, reduced neuroplasticity, and social withdrawal. Action steps: Seek professional evaluation; psychotherapy, medication, exercise, and social engagement all help.

Physical Inactivity

Exercise protects the brain through increased cerebral blood flow, BDNF production, reduced inflammation, and improved insulin sensitivity. Aerobic activity has the strongest evidence. Action steps: Aim for at least 150 minutes of moderate aerobic activity weekly; even walking helps. Physical activity also supports plasmalogen biosynthesis, a bridge to Part 2.

Diabetes

Insulin resistance and chronic hyperglycemia damage cerebral vasculature and impair neuronal energy metabolism. Type 2 diabetes roughly doubles dementia risk. Action steps: Monitor glucose, eat a low-glycemic diet, stay active, and adhere to medication.

Later-Life Risk Factors: Protecting the Aging Brain

After age 65, risk factor management remains impactful, even if leverage is somewhat lower. These factors are still highly actionable.

Excessive Alcohol Consumption

Heavy drinking is neurotoxic; the Commission does not endorse low-level drinking as protective. Mechanisms include direct neuronal damage, thiamine deficiency, and increased stroke risk. Action step: Follow national guidelines and seek support for alcohol use disorder.

Traumatic Brain Injury (TBI)

Even moderate concussions can trigger neuroinflammation and accelerate amyloid-beta accumulation, with repeated injuries compounding risk. Action steps: Wear protective gear, adopt fall-prevention programs for older adults, and limit contact-sport head impacts.

Air Pollution

Fine particulate matter (PM2.5) and nitrogen dioxide cross the blood-brain barrier, causing neuroinflammation and oxidative stress. Action steps: Use indoor air purifiers, avoid high-traffic areas during exercise, and support clean-air policies.

Social Isolation

Chronic loneliness reduces cognitive stimulation and elevates stress hormones, accelerating brain aging. Action steps: Maintain close relationships, join community groups, volunteer, and stay socially active.

Untreated Vision Loss (New in 2024)

The second 2024 addition, untreated vision loss reduces environmental engagement and may share pathways with neurodegeneration, since the retina is an extension of the brain. Plasmalogens are highly concentrated in the retina, bridging to Part 2. Action steps: Get regular eye exams and prompt treatment for cataracts, glaucoma, and macular degeneration. Tips on how to improve eyesight after 50 can be a useful starting point for those concerned about age-related vision changes.

The Gap in Every Prevention Guide: What the Lancet Framework Does Not Cover

The Lancet framework is the gold standard of behavioral dementia prevention. A critical question remains, however: if 45% of cases stem from these 14 factors, what explains the other 55%? And why do some people who follow every guideline still develop dementia?

The answer points to a biochemical layer: the structural integrity of neuronal membranes, specifically plasmalogens. No mainstream guide from the NHS, Alzheimer’s Society, or Johns Hopkins integrates this dimension. This section is additive, not contradictory. It explains why the brain becomes vulnerable in the first place.

The Biochemical Layer: What Are Plasmalogens and Why Do They Matter?

Plasmalogens are a specialized class of phospholipids, constituting 18 to 20% of total phospholipids in cell membranes, with high concentrations in the brain, retina, heart, and immune cells. They perform three core brain functions: (1) membrane stability and fluidity for efficient neurotransmission; (2) mitochondrial efficiency for cellular energy; and (3) antioxidant defense by scavenging reactive oxygen species.

If neurons are the brain’s hardware, plasmalogens are the protective coating that keeps that hardware running. According to the Journal of Lipid Research, more than 100 publications per year now focus on plasmalogens, with Alzheimer’s, Parkinson’s, and multiple sclerosis consistently associated with reduced levels. This is active, peer-reviewed science.

How Plasmalogens Decline With Age, and What That Means for Dementia Risk

Plasmalogen levels peak in early adulthood, then decline progressively, with roughly 40% lost by age 70. A significant subpopulation shows dramatic decline between ages 50 and 69, precisely the midlife window the Lancet identifies as highest-leverage.

Research published in Alzheimer’s & Dementia: Translational Research found that serum ethanolamine plasmalogen levels begin decreasing years before clinical symptoms, and that across five independent populations, depletion severity correlated with disease severity. Work in Brain Communications shows ethanolamine plasmalogen deficiency mirrors the Alzheimer’s risk gradient tied to APOE ε4 dose. The vulnerability is also sex-specific: women account for nearly two-thirds of U.S. Alzheimer’s cases, and 2025 lipidomic research links lipid alterations more strongly to Alzheimer’s in women.

The Peroxisome Connection: Why Plasmalogen Synthesis Breaks Down

Plasmalogen biosynthesis is initiated exclusively in peroxisomes. A vicious cycle results when these organelles fail: reduced synthesis impairs membrane integrity and antioxidant defense, increasing amyloid-beta accumulation, which further suppresses peroxisomal function. Research in Acta Neuropathologica found plasmalogens decreased in severely affected Alzheimer’s brain tissue, consistent with early peroxisomal dysfunction. Critically, several Lancet factors (physical inactivity, obesity, diabetes, and high LDL) impair peroxisomal function. This is why lifestyle and biochemical support are complementary, not competing.

Plasmalogens vs. Amyloid: Rethinking the Sequence of Events

Most public understanding centers on amyloid plaques and tau tangles. Yet postmortem measurements show membrane plasmalogen content in the cortex and hippocampus correlates with dementia severity more strongly than amyloid burden alone. Low plasmalogen levels predicted Alzheimer’s independently of beta-amyloid and tau, suggesting depletion may precede plaque buildup. In other words, the brain may become vulnerable to amyloid because its membrane defenses were already compromised. Waiting for amyloid biomarkers may mean waiting too long.

Can Plasmalogen Levels Be Measured and Restored?

Plasmalogen levels are measurable through blood testing, making them a quantifiable, trackable biomarker unlike many other risk factors. Comprehensive lipid panels can assess ethanolamine plasmalogens (PlsEtn) and choline plasmalogens (PlsCho).

Because synthesis declines with age and peroxisomal dysfunction, targeted nutritional support may help restore levels. A 2023 dietary lipid review found plasmalogen more effective than phosphatidylserine in alleviating age-related cognitive impairment. A 2025 FASEB BioAdvances review cautioned that insufficient dosage and limited bioavailability explain why some studies showed no benefit, meaning formulation quality matters. Different regions also need different support: gray matter relies on DHA/omega-3 plasmalogens, while white matter relies on oleic acid/omega-9 plasmalogens.

How Prodrome Science Approaches the Biochemical Layer

Prodrome Science was founded on more than 30 years of lipid and metabolomic research by Dr. Dayan Goodenowe, PhD, the first to design, patent, and develop targeted plasmalogen precursors. The company’s “prodrome” philosophy aims to optimize biochemistry before illness takes root, complementing the Lancet behavioral framework.

Its precursors are engineered to bypass gut degradation and are delivered at significantly higher concentrations (900 mg per serving) than typical alternatives. Two targeting strategies address different brain tissue: ProdromeNeuro™/PlasmalogenN3™ (omega-3 precursors for gray matter) and ProdromeGlia™ (omega-9 precursors for white matter). The ProdromeScan™ blood panel measures over 40 biomarkers, including plasmalogens, enabling a “measure first” approach. The ProdromeScan™ is available to qualified health professionals; consumers should contact Prodrome Science directly to discuss eligibility. These are dietary supplements; statements have not been evaluated by the FDA, and products are not intended to diagnose, treat, cure, or prevent any disease.

Bringing It Together: A Two-Layer Prevention Strategy

Effective prevention operates on two complementary layers: the behavioral layer (the 14 Lancet factors) and the biochemical layer (plasmalogen integrity). They reinforce each other. Physical activity, healthy weight, and LDL management all support peroxisomal function and plasmalogen biosynthesis.

The Lancet framework identifies what to do; plasmalogen science explains why it works at the cellular level and what additional support may help when synthesis declines. Both layers are most impactful in midlife. APOE ε4 carriers, women, and those with a family history may have heightened need to monitor levels.

Conclusion: Prevention Is a Two-Front Strategy

The 2024 Lancet Commission’s 14 modifiable risk factors represent the most powerful behavioral toolkit for dementia prevention ever assembled, capable of preventing or delaying nearly half of all cases. Yet no mainstream guide integrates the biochemical dimension that helps explain why the brain becomes vulnerable.

The two-layer framework is straightforward: (1) address the 14 lifestyle factors, starting in midlife; (2) monitor and support plasmalogen levels as a measurable biomarker. With plasmalogen research advancing at over 100 publications per year, those who act now are ahead of the curve. As Alzheimer’s Disease International notes, addressing these factors early, especially in lower-resourced settings, represents a profound opportunity to reduce the global burden.

Ready to Go Beyond the Standard Checklist?

For those ready to go deeper, the next step is understanding the biochemistry behind brain resilience.

• Learn more: Explore plasmalogen science and Prodrome Science’s approach to brain membrane health.
• Measure a baseline: Ask a qualified health professional about the ProdromeScan™ biomarker test to assess plasmalogen levels.
• Read further: Dr. Dayan Goodenowe’s book, Breaking Alzheimer’s, offers a deeper dive into plasmalogen depletion and brain health. For additional strategies on improving your memory, explore resources that complement the biochemical approach outlined here.

Prodrome Science products are dietary supplements, and working with a qualified health professional is recommended for personalized guidance. If this two-layer framework is useful, consider sharing it with a caregiver, family member, or health professional who may benefit.